Poltava Medical Glass Plant JSC (PMGP, Poltava) saw its net profit decline by 15.8% in January–September 2026 compared to the same period in 2025, down to 66.05 million UAH.
According to the company’s interim report filed with the National Securities and Stock Market Commission’s disclosure system, its net sales revenue rose by 25.3% to 329.2 million UAH.
In January–September, the plant generated UAH 72.9 million in operating profit (down 14%), while gross profit increased slightly to UAH 107.5 million.
During this period, the plant manufactured 263 million ampoules and shipped 432.5 million units worth UAH 311 million.
The company generated 17.3 million UAH from the sale of oxygen and nitrogen.
As previously reported, in 2025, PZMS saw its net profit decline by 19% compared to 2024—to 105.564 million UAH—due to a 3.5% decrease in net revenue, which fell to 364.281 million UAH.
According to data from the National Securities and Stock Market Commission as of August 2026, 59.7% of the company’s authorized capital is owned by Supervisory Board Chairman Leonid Nekrasov, nearly 10% by Management Board Chairman Oleksandr Kudatsky, and another 25% is held by the pharmaceutical manufacturer PJSC “Ukrmedprom” (Kyiv), which falls under the jurisdiction of the Ministry of Health of Ukraine.
According to information on its website, the Poltava Medical Glass Plant is Ukraine’s leading manufacturer of ampoules for pharmaceuticals.
ampoule, PHARMACEUTICALS, Poltava Medical Glass Plant, PRODUCTION, PROFIT
